Lodestone Wealth Management LLC Invests $8.37 Million in BioNTech SE

Lodestone Wealth Management LLC has recently made a significant investment in BioNTech SE (NASDAQ:BNTX). In its latest 13F filing with the Securities and Exchange Commission (SEC), the firm revealed that it acquired a new stake in BioNTech during the third quarter. Specifically, Lodestone purchased 70,500 shares of the company’s stock, totaling approximately $8,373,000. This investment now represents 4.1% of Lodestone's total holdings, making BioNTech its largest investment.

In addition to Lodestone, several other institutional investors have also shown interest in BioNTech. Notably, Covestor Ltd increased its stake by 47.2% in the first quarter, now owning 415 shares valued at $38,000 after acquiring an additional 133 shares. Blue Trust Inc. made a more dramatic increase, boosting its position by 491.1% in the third quarter and now holds 467 shares worth $55,000 following a purchase of 388 shares.

Meanwhile, EverSource Wealth Advisors LLC raised its holdings by 106.3% in the first quarter, owning 489 shares valued at $43,000, which is after buying an additional 252 shares. GAMMA Investing LLC also increased its investment, adding 86.9% more shares during the second quarter and now holds 512 shares worth $41,000. Crewe Advisors LLC has acquired a new position in BioNTech, with an investment totaling around $75,000 in the first quarter. Currently, institutional investors own about 15.52% of BioNTech's stock.

BioNTech Stock Overview

The stock price of BioNTech opened at $111.48 recently. With a current market capitalization of approximately $26.51 billion, BioNTech has a price-to-earnings ratio of -49.33, indicating that it has negative earnings. The beta of the stock is 0.26, suggesting that it is less volatile compared to the market. Over the last fifty days, the moving average price has been around $109.72, while the 200-day moving average stands at $95.77. The company shows strong liquidity with a quick ratio of 7.40 and a current ratio of 7.54. Its debt-to-equity ratio is very low at 0.01, reflecting a solid financial position. Over the past year, BioNTech’s stock has fluctuated between a low of $76.53 and a high of $131.49.

Recent Earnings and Analyst Opinions

BioNTech recently shared its quarterly earnings data showing a loss. In its latest report on August 5th, the company announced an earnings per share (EPS) loss of $3.36, which fell short of analysts' expectations that predicted a loss of $2.02 by $1.34. The company reported revenues of $128.70 million, which were below the analysts' forecast of $134.98 million, marking a decrease of 23.3% year-over-year. Sales forecasts for the current fiscal year suggest an EPS of -2.93.

Analysts have recently made various updates on their ratings for BioNTech. UBS Group raised its price target from $97.00 to $131.00 and maintained a "neutral" rating. JPMorgan Chase upgraded BioNTech from an "underweight" rating to "neutral" while raising their price target to $125.00, an increase from $91.00. Similarly, TD Cowen raised its target price to $132.00 from $85.00, while Jefferies Financial Group upgraded its rating from "hold" to "buy" with a target price of $150.00. HSBC also increased its target from $97.00 to $136.00. The general sentiment shows that five analysts have rated BioNTech as a hold, eight have given it a buy rating, and one has assigned a strong buy rating. The average rating for BioNTech stands as a "Moderate Buy" with a target price averaging around $135.54.

About BioNTech SE

BioNTech SE is a biotechnology company that specializes in developing and commercializing immunotherapies for various diseases, including cancer and infectious diseases. The firm is actively involved in the development of several promising product candidates including BNT111 for advanced melanoma, BNT112 for prostate cancer, and BNT113 for HPV 16+ related head and neck cancers, among others. Through its innovative eforts, BioNTech aims to play a significant role in advancing medical treatments.

Investment, BioNTech, Stocks